Feel the real temperature of the Chinese economy, witness the pace of the dream-driven era. who can represent the strongest driving force for business 2019? On January 9,2020, the 2019 Big Ten Economic Person of the Year Awards ceremony will be held in Beijing 751D MARK Grand, please look forward to it. 【】
BEIJING, Jan.3(Xinhua)-- The State Organization's Office for Centralized Drug Purchase and Use of Joint Purchasing has issued a national centralized drug procurement document with 33 varieties included in the list of the second batch of national drugs, covering major chronic diseases such as hypertension and diabetes, as well as anti-tumor and rare diseases.
According to the centralized procurement work arrangement, the bid opening will produce the result of the proposed selection on January 17,2020, and patients from all over the country will use the second batch of concentrated belt quantity to purchase the selected drugs in April this year. Some netizens commented that another wave of reduced prices had been \"on the way \".
The reporter combed and found that the list included acarbose, glimepiride and other oral hypoglycemic drugs; omesartan ester, candesartan ester, indapamide and other hypertension medication; treatment of rare diseases-pulmonary arterial hypertension drug Anlishengtan tablets, as well as anticancer drugs tegio, abitron and so on; as well as azithromycin, metronidazole, moxifloxacin, ceflatin and other antibiotic varieties.
It is worth noting that the second batch of national drug \"collection\" in addition to expanding varieties, procurement programs are more mature, and implemented simultaneously in the country, showing that the drug centralized belt quantity procurement system has entered into a standardized, regular operation. Some of the self-funded varieties that are not included in the health care catalogue are also added to the collection this time. Industry insiders point out that this means that self-financed drugs will also feel the \"pressure\" to reduce prices brought on by concentrated purchases.
In September 2019, the first batch of national drug \"collection\" expanded to the whole country, compared with the lowest purchase price of the same varieties in the area in 2018, the average decline of 25 selected drugs was 59%.
Industry insiders pointed out that from the results achieved so far, with the procurement model to guide drug prices, has become a major trend. This includes not only the drugs on the national \"collection\" list, but also the drugs that are not included in the national \"collection \". As a result, there will be more drugs to reduce prices in 2020 and a wider range of patients to benefit.
For example, the Circular on Further Promoting the Experiences of Deepening the Reform of the Medical and Health System in Fujian Province and Sanming Municipality, issued recently by the Leading Group on Deepening the Reform of the Medical and Health System of the State Council, has made it clear that all localities should actively adopt individual or cross-regional alliances to purchase drugs that are not included in the centralized procurement and use of pharmaceuticals, with a budget, in accordance with the requirements of quantity-based procurement, integration of recruitment, quality priority, ensuring the use of drugs and ensuring the return of funds. By the end of September 2020, the pilot provinces of comprehensive medical reform should take the lead in exploring, and other provinces should also actively explore.